The content on this site is intended for healthcare professionals only
Asciminib found to be safe and effective for heavily pretreated patients with ch...
Dr Michael Mauro - Memorial Sloan Kettering Cancer Center, New York, USA
14 Dec 2021
Long-term OS benefit with oral azacitidine for acute myeloid leukaemia in first ...
Prof Andrew Wei - Monash University, Melbourne, Australia
13 Dec 2021
Allogeneic haematopoietic cell transplantation in adults with Ph-like ALL
Dr Ibrahim Aldoss - City of Hope, Duarte, USA
13 Dec 2021
Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston...
13 Dec 2021
Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes ...
Dr Abhishek Maiti - The University of Texas MD Anderson Cancer Center, Houston, ...
13 Dec 2021
Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory larg...
Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA
13 Dec 2021
EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free ...
Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France
13 Dec 2021
Real world data supports ciltacabtagene autoleucel as effective option for tripl...
Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Sp...
12 Dec 2021
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with...
Dr Martin Kaiser - The Institute of Cancer Research, London UK
12 Dec 2021
Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted cons...
Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA
12 Dec 2021
Latest in combination therapy for NDMM patients
Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA
12 Dec 2021
Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail pa...
Dr Guido Gini - Università Politecnica delle Marche, Ancona, Italy
11 Dec 2021